Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
AbbVie acquired Stemcentrx for up to $9.8B to enhance oncology pipeline.
AbbVie acquired Stemcentrx for its novel late-stage Rova-T compound showing 44% response rates in DLL3-expressing small cell lung cancer — an area of enormous…
Rova-T: the story of AbbVie's multi-billion dollar failure. Even without hindsight, buying Stemcentrx outright for $5.8B based on Phase 1 data looked bold at…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
AbbVie acquired Stemcentrx for up to $9.8B to enhance oncology pipeline.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Stemcentrx Inc. (this deal) | 2012 | $5.8B | 16 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2012 deals · AbbVie Inc. deals · Oncology deals